Literature DB >> 19022533

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

Shanu Kohli Kurd1, Joel M Gelfand.   

Abstract

BACKGROUND: Psoriasis is a predictor of morbidity. It is important to determine the extent to which psoriasis remains undiagnosed.
OBJECTIVE: To determine the prevalence of psoriasis.
METHODS: We conducted a cross-sectional study using the National Health and Nutrition Examination Survey 2003-2004.
RESULTS: The prevalence of diagnosed psoriasis was 3.15% (95% confidence interval [CI], 2.18-4.53), corresponding to 5 million adults. Approximately 17% of these patients have moderate to severe psoriasis based on body surface area report and 25% rate psoriasis a large problem in everyday life. The prevalence of undiagnosed active psoriasis by conservative estimate was 0.4% (95% CI, 0.19-0.82), corresponding to approximately 600,000 US adults, and 2.28% (95% CI, 1.47-3.50) by a broader definition, corresponding to 3.6 million US adults. Undiagnosed patients had a trend toward being more likely to be male, nonwhite, less educated, and unmarried compared with patients who had received a diagnosis. LIMITATIONS: The method for determining the presence of psoriasis had limited ability to detect mild disease and only fair interrater agreement.
CONCLUSION: More than 5 million adults have been diagnosed with psoriasis. A large number have undiagnosed psoriasis and there are important disparities which may be associated with not receiving medical attention.

Entities:  

Mesh:

Year:  2008        PMID: 19022533      PMCID: PMC4762027          DOI: 10.1016/j.jaad.2008.09.022

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  29 in total

1.  Validation of self-reported chronic conditions and health services in a managed care population.

Authors:  L M Martin; M Leff; N Calonge; C Garrett; D E Nelson
Journal:  Am J Prev Med       Date:  2000-04       Impact factor: 5.043

2.  Psoriasis on the Faroe Islands; a preliminary report.

Authors:  G LOMHOLT
Journal:  Acta Derm Venereol       Date:  1954       Impact factor: 4.437

3.  Low prevalence of psoriasis in Norwegian lapps.

Authors:  G Kavli; S E Stenvold; O Vandbakk
Journal:  Acta Derm Venereol       Date:  1985       Impact factor: 4.437

4.  Skin conditions and related need for medical care among persons 1-74 years. United States, 1971-1974.

Authors:  M T Johnson; J Roberts
Journal:  Vital Health Stat 11       Date:  1978-11

5.  Determinants of quality of life in patients with psoriasis: a study from the US population.

Authors:  Joel M Gelfand; Steven R Feldman; Robert S Stern; John Thomas; Tara Rolstad; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2004-11       Impact factor: 11.527

6.  National Psoriasis Foundation clinical consensus on disease severity.

Authors:  David M Pariser; Jerry Bagel; Joel M Gelfand; Neil J Korman; Christopher T Ritchlin; Bruce E Strober; Abby S Van Voorhees; Melodie Young; Sheila Rittenberg; Mark G Lebwohl; Elizabeth J Horn
Journal:  Arch Dermatol       Date:  2007-02

7.  Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

Authors:  J Koo
Journal:  Dermatol Clin       Date:  1996-07       Impact factor: 3.478

8.  The prevalence of psoriasis in Denmark.

Authors:  F Brandrup; A Green
Journal:  Acta Derm Venereol       Date:  1981       Impact factor: 4.437

Review 9.  Epidemiology of psoriasis.

Authors:  Luigi Naldi
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2004-06

10.  Skin disease in Lambeth. A community study of prevalence and use of medical care.

Authors:  J N Rea; M L Newhouse; T Halil
Journal:  Br J Prev Soc Med       Date:  1976-06
View more
  133 in total

Review 1.  The genetics of psoriasis and psoriatic arthritis.

Authors:  Vinod Chandran
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 2.  Assessing long-term drug safety: lessons (re) learned from raptiva.

Authors:  Nicole M Seminara; Joel M Gelfand
Journal:  Semin Cutan Med Surg       Date:  2010-03

3.  Validity of The Health Improvement Network (THIN) for the study of psoriasis.

Authors:  N M Seminara; K Abuabara; D B Shin; S M Langan; S E Kimmel; D Margolis; A B Troxel; J M Gelfand
Journal:  Br J Dermatol       Date:  2011-02-03       Impact factor: 9.302

Review 4.  Clinical and histologic diagnostic guidelines for psoriasis: a critical review.

Authors:  Mary Ann N Johnson; April W Armstrong
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

5.  Psoriasis and cardiovascular risk: strength in numbers, part II.

Authors:  Joel M Gelfand; Nehal N Mehta; Sinéad M Langan
Journal:  J Invest Dermatol       Date:  2011-05       Impact factor: 8.551

Review 6.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

Review 7.  The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Erica D Dommasch; Katrina Abuabara; Daniel B Shin; Josephine Nguyen; Andrea B Troxel; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2011-02-18       Impact factor: 11.527

8.  Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice.

Authors:  Lynda Grine; Lien Dejager; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

9.  Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis.

Authors:  E D Dommasch; D B Shin; A B Troxel; D J Margolis; J M Gelfand
Journal:  Br J Dermatol       Date:  2009-11-10       Impact factor: 9.302

10.  Pituitary tumor transforming gene PTTG2 induces psoriasis by regulating vimentin and E-cadherin expression.

Authors:  Xiao-Bing Liu; Feng Li; Ya-Qin Li; Fan Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.